The goal of this clinical trial is to learn more about the enteric nervous system (ENS) and the intestinal epithelial barrier (IEB) in patients with spinal cord injury (SCI). The main questions it aims to answer are : * to characterize the functional (permeability, serotonin production, enteric neuronal phenotype, etc.), proteomic (junction molecules) and transcriptomic (inflammation genes, neuromediator expression, etc.) remodeling of the colonic mucosa and ENS in SCI patients, in comparison with control data. * to correlate intestinal permeability (and all remodeling parameters) with the type of neurological impairment i.e. the neurological level of the lesion, quantification of neurological impairment (motor and sensory scores) and the completeness and incompleteness of a lesion. * to identify a link with disease severity markers * to identify therapeutic targets that could subsequently be tested in the animal model before being proposed in clinical trials. Participants will have colonic biopsies taken following a colonoscopy/rectosigmoidoscopy previously indicated for spinal cord injured patients. Biopsies will be obtained from the right and left colon.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Measurement of sulfonic acid and HRP flux in biopsies placed in Ussing chamber
Timeframe: 1 month
Quantifying the expression of junction molecules of the ZO-1 type
Timeframe: 1 month
Number of serotonin-producing cells labelled with anti-5-HT antibody
Timeframe: 1 month
The degree of expression of TPH1 and SERT in RT-qPCR
Timeframe: 1 month
Calculation of the number of neurons and the proportion of different neurochemical phenotypes of neurons in relation to the total number of neurons in the submucosal plexus
Timeframe: 1 month
VIP, ACh and 5-HT concentration in the colonic mucosa
Timeframe: 1 month
Expression levels of key inflammation cytokines (TNFα, IL 1β, IFNɣ...)
Timeframe: 1 month